Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.0%

1 terminated out of 20 trials

Success Rate

91.7%

+5.2% vs benchmark

Late-Stage Pipeline

15%

3 trials in Phase 3/4

Results Transparency

18%

2 of 11 completed with results

Key Signals

2 with results92% success

Data Visualizations

Phase Distribution

14Total
Not Applicable (6)
P 1 (2)
P 2 (3)
P 4 (3)

Trial Status

Completed11
Recruiting3
Active Not Recruiting2
Withdrawn2
Terminated1
Unknown1

Trial Success Rate

91.7%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT05164016Completed

Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients

NCT06529536Phase 4RecruitingPrimary

Utilising Genotype Informed Bayesian Dosing of Tacrolimus in Children Post Solid Organ Transplantation.

NCT04613206Phase 2Active Not Recruiting

High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients

NCT04331275Phase 2Active Not RecruitingPrimary

Viral Specific T-cells for Treatment of Viral Infections After Solid Organ Transplant

NCT05550298Recruiting

Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients

NCT03360682Phase 4Completed

Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients

NCT05663463Not ApplicableCompletedPrimary

Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients

NCT05968807Not ApplicableRecruitingPrimary

iParent2Parent Program for Parents of Pediatric Solid Organ Transplant Recipients

NCT03950414Phase 1Terminated

A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients

NCT05121142Phase 1Completed

Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease

NCT04253548Not ApplicableCompletedPrimary

iPeer2Peer Pediatric Thoracic Transplantation

NCT04844489Not ApplicableCompleted

Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People

NCT04721288Not ApplicableUnknownPrimary

REmote moBile Outpatient mOnitoring in Transplant 2.0

NCT05124509Completed

Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant

NCT03327987Withdrawn

Early Flu Shots in SOT

NCT02165423Not ApplicableCompletedPrimary

Discharge to Home and Chronic Illness Care Pilot

NCT02464306Phase 4Withdrawn

Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection

NCT01058239Phase 2Completed

Bortezomib Plus Rituximab for EBV+ PTLD

NCT00907023CompletedPrimary

Transition From Hospital to Home in Solid Organ Transplant (SOT)

NCT00518778CompletedPrimary

Fusariosis in Solid-Organ Transplant Recipients

Showing all 20 trials

Research Network

Activity Timeline